Diabetes - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
CCND2 and CDKN2A	cyclin D2	cyclin-dependent kinase inhibitor 2A	Cyclin D associated events in G1 G1 Phase Mitotic G1-G1/S phases Cell Cycle, Mitotic	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence
CCNG1 and CDKN2A	cyclin G1	cyclin-dependent kinase inhibitor 2A		Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence
CD3E and PTPN22	CD3e molecule, epsilon (CD3-TCR complex)	protein tyrosine phosphatase, non-receptor type 22 (lymphoid)	TCR signaling Downstream TCR signaling Generation of second messenger molecules Translocation of ZAP-70 to Immunological synapse Costimulation by the CD28 family PD-1 signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Phosphorylation of CD3 and TCR zeta chains Adaptive Immune System		Muromonab
CD247 and SH2B3	CD247 molecule	SH2B adaptor protein 3		Signaling by SCF-KIT Regulation of KIT signaling Factors involved in megakaryocyte development and platelet production
CD247 and PTPN22	CD247 molecule	protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
CD4 and IL2RA	CD4 molecule	interleukin 2 receptor, alpha	Vpu mediated degradation of CD4 Downstream TCR signaling Generation of second messenger molecules Translocation of ZAP-70 to Immunological synapse Costimulation by the CD28 family Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters HIV Infection Host Interactions of HIV factors The role of Nef in HIV-1 replication and disease pathogenesis Early Phase of HIV Life Cycle HIV Life Cycle TCR signaling Alpha-defensins PD-1 signaling Defensins Phosphorylation of CD3 and TCR zeta chains Nef Mediated CD4 Down-regulation Binding and entry of HIV virion Innate Immune System Adaptive Immune System	Signaling by GPCR G-protein beta:gamma signalling Cytokine Signaling in Immune system Signaling by Interleukins GPCR downstream signaling Interleukin receptor SHC signaling G beta:gamma signalling through PI3Kgamma Interleukin receptor SHC signaling GPVI-mediated activation cascade Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling		Denileukin diftitox Aldesleukin Basiliximab Daclizumab
CD80 and CTLA4	CD80 molecule	cytotoxic T-lymphocyte-associated protein 4	Signaling by the B Cell Receptor (BCR) Costimulation by the CD28 family Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF Signalling by NGF DAP12 interactions GAB1 signalosome CD28 co-stimulation CTLA4 inhibitory signaling CD28 dependent PI3K/Akt signaling Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling CD28 dependent Vav1 pathway Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Costimulation by the CD28 family CTLA4 inhibitory signaling Adaptive Immune System	Abatacept Belatacept	Alpha-D-Mannose
CD86 and CTLA4	CD86 molecule	cytotoxic T-lymphocyte-associated protein 4	Signaling by the B Cell Receptor (BCR) Costimulation by the CD28 family Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signaling by PDGF Signalling by NGF DAP12 interactions GAB1 signalosome CD28 co-stimulation CTLA4 inhibitory signaling CD28 dependent PI3K/Akt signaling Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling CD28 dependent Vav1 pathway Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Costimulation by the CD28 family CTLA4 inhibitory signaling Adaptive Immune System	Antithymocyte globulin Abatacept Belatacept	Alpha-D-Mannose
CD53 and IL2	CD53 molecule	interleukin 2		Signaling by GPCR G-protein beta:gamma signalling Cytokine Signaling in Immune system Signaling by Interleukins GPCR downstream signaling Interleukin receptor SHC signaling G beta:gamma signalling through PI3Kgamma Interleukin receptor SHC signaling GPVI-mediated activation cascade Interleukin-2 signaling Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling		SP4160 5-[2,3-Dichloro-4-(5-{1-[2-(2-Guanidino-4-Methyl-Pentanoylamino)-Acetyl]-Piperidin-4-Yl}-1-Methyl-1h-Pyrazol-3-Yl)-Phenoxymethyl]-Furan-2-Carboxylic Acid 3-Mercapto-1-(1,3,4,9-Tetrahydro-B-Carbolin-2-Yl)-Propan-1-One (R)-N-[2-[1-(Aminoiminomethyl)-3-Piperidinyl]-1-Oxoethyl]-4-(Phenylethynyl)-L-Phenylalanine Methylester (1h-Indol-3-Yl)-(2-Mercapto-Ethoxyimino)-Acetic Acid SP2456 2-[2-(2-Cyclohexyl-2-Guanidino-Acetylamino)-Acetylamino]-N-(3-Mercapto-Propyl)-Propionamide
CDK1 and PTPN2	cyclin-dependent kinase 1	protein tyrosine phosphatase, non-receptor type 2	Phosphorylation of the APC/C Signaling by FGFR in disease Phosphorylation of Emi1 Signaling by EGFRvIII in Cancer Toll Like Receptor TLR1:TLR2 Cascade Toll Like Receptor 5 (TLR5) Cascade Gastrin-CREB signalling pathway via PKC and MAPK MyD88 dependent cascade initiated on endosome SOS-mediated signalling Mitotic G1-G1/S phases SHC-mediated signalling Recruitment of mitotic centrosome proteins and complexes TRIF-mediated TLR3/TLR4 signaling ERK1 activation Nuclear Pore Complex (NPC) Disassembly APC/C:Cdc20 mediated degradation of mitotic proteins Regulation of APC/C activators between G1/S and early anaphase ERK1 activation APC/C:Cdc20 mediated degradation of Cyclin B Signaling by VEGF Resolution of Sister Chromatid Cohesion Downstream signal transduction Signalling to RAS Toll Like Receptor 3 (TLR3) Cascade Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint Interleukin-2 signaling Mitotic G2-G2/M phases Frs2-mediated activation MASTL Facilitates Mitotic Progression Axon guidance IRS-mediated signalling G2/M Transition VEGFA-VEGFR2 Pathway Activated TLR4 signalling VEGFR2 mediated cell proliferation GRB2 events in ERBB2 signaling Cyclin A/B1 associated events during G2/M transition Loss of Nlp from mitotic centrosomes MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation NCAM signaling for neurite out-growth RAF/MAP kinase cascade Signalling to p38 via RIT and RIN Innate Immune System Condensation of Prometaphase Chromosomes Signaling by Insulin receptor E2F mediated regulation of DNA replication Insulin receptor signalling cascade Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes G0 and Early G1 Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events SHC-related events Signaling by FGFR ARMS-mediated activation Toll-Like Receptors Cascades Toll Like Receptor 10 (TLR10) Cascade Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) E2F-enabled inhibition of pre-replication complex formation Regulation of mitotic cell cycle Cell Cycle Checkpoints Signaling by GPCR G2/M Checkpoints Mitotic Prophase Golgi Cisternae Pericentriolar Stack Reorganization FCERI mediated MAPK activation Regulation of PLK1 Activity at G2/M Transition SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling G1/S Transition G1/S-Specific Transcription Toll Like Receptor 9 (TLR9) Cascade G2/M DNA replication checkpoint Signaling by PDGF DAP12 interactions SHC-related events triggered by IGF1R GRB2 events in EGFR signaling Signaling by ERBB4 APC/C-mediated degradation of cell cycle proteins Toll Like Receptor 2 (TLR2) Cascade Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins SHC1 events in ERBB4 signaling Toll Like Receptor 4 (TLR4) Cascade Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Condensation of Prophase Chromosomes Signaling by Leptin Signalling to ERKs Mitotic Prometaphase Prolonged ERK activation events Organelle biogenesis and maintenance ERK activation Toll Like Receptor 7/8 (TLR7/8) Cascade Activation of NIMA Kinases NEK9, NEK6, NEK7 Nuclear Envelope Breakdown IGF1R signaling cascade Recruitment of NuMA to mitotic centrosomes Cyclin B2 mediated events Toll Like Receptor TLR6:TLR2 Cascade M Phase IRS-related events triggered by IGF1R MyD88 cascade initiated on plasma membrane ERK activation Downstream signaling of activated FGFR Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Signalling by NGF SOS-mediated signalling G2/M DNA damage checkpoint MAP kinase activation in TLR cascade SHC-mediated signalling Depolymerisation of the Nuclear Lamina Assembly of the primary cilium Cytokine Signaling in Immune system NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer MyD88-independent cascade Anchoring of the basal body to the plasma membrane Cell Cycle, Mitotic SHC1 events in EGFR signaling Loss of proteins required for interphase microtubule organizationÂ from the centrosome FRS2-mediated cascade IRS-mediated signalling Centrosome maturation		Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone
CDC5L and CDKN2A	cell division cycle 5-like	cyclin-dependent kinase inhibitor 2A	Processing of Capped Intron-Containing Pre-mRNA mRNA Splicing mRNA Splicing - Major Pathway	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence
CDC6 and CDKN2A	cell division cycle 6	cyclin-dependent kinase inhibitor 2A	CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Activation of the pre-replicative complex Activation of the pre-replicative complex Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Assembly of the pre-replicative complex Activation of ATR in response to replication stress G1/S Transition G1/S-Specific Transcription Removal of licensing factors from origins Mitotic G1-G1/S phases Switching of origins to a post-replicative state E2F mediated regulation of DNA replication Synthesis of DNA DNA Replication Pre-Initiation Regulation of DNA replication M/G1 Transition G0 and Early G1 S Phase CDC6 association with the ORC:origin complex Cell Cycle, Mitotic Orc1 removal from chromatin Cell Cycle Checkpoints CDT1 association with the CDC6:ORC:origin complex Association of licensing factors with the pre-replicative complex	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence
CDC34 and PPARG	cell division cycle 34	peroxisome proliferator-activated receptor gamma	Antigen processing: Ubiquitination & Proteasome degradation Class I MHC mediated antigen processing & presentation Adaptive Immune System	PPARA activates gene expression Fatty acid, triacylglycerol, and ketone body metabolism Metabolism of lipids and lipoproteins Generic Transcription Pathway Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)		Icosapent Troglitazone Mesalazine Indomethacin Rosiglitazone Nateglinide Sulfasalazine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Pioglitazone Mitiglinide Bezafibrate (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid ALEGLITAZAR
CDK2 and PRC1	cyclin-dependent kinase 2	protein regulator of cytokinesis 1	CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Activation of the pre-replicative complex Cellular Senescence Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes G2/M Transition p53-Dependent G1/S DNA damage checkpoint Activation of the pre-replicative complex Orc1 removal from chromatin Cyclin E associated events during G1/S transition CDK-mediated phosphorylation and removal of Cdc6 p53-Dependent G1 DNA Damage Response Cyclin A/B1 associated events during G2/M transition G2 Phase Activation of ATR in response to replication stress G1/S Transition Removal of licensing factors from origins Mitotic G1-G1/S phases Switching of origins to a post-replicative state G1/S DNA Damage Checkpoints Meiotic recombination DNA Damage/Telomere Stress Induced Senescence Synthesis of DNA DNA Replication Pre-Initiation M/G1 Transition Regulation of DNA replication Senescence-Associated Secretory Phenotype (SASP) G0 and Early G1 S Phase Regulation of APC/C activators between G1/S and early anaphase Factors involved in megakaryocyte development and platelet production Cell Cycle, Mitotic APC/C-mediated degradation of cell cycle proteins SCF(Skp2)-mediated degradation of p27/p21 Orc1 removal from chromatin Regulation of mitotic cell cycle Cell Cycle Checkpoints SCF(Skp2)-mediated degradation of p27/p21 Cyclin A:Cdk2-associated events at S phase entry Mitotic G2-G2/M phases		Double Oxidized Cysteine 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide Staurosporine Indirubin-3\'-Monoxime 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine Olomoucine 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide 2-Amino-6-Chloropyrazine 6-O-Cyclohexylmethyl Guanine N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide 1-Amino-6-Cyclohex-3-Enylmethyloxypurine N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide Purvalanol [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine Hymenialdisine (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline SU9516 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole Flavopiridol (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One Lysine Nz-Carboxylic Acid [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone Alsterpaullone N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE OLOMOUCINE II TRIAZOLOPYRIMIDINE Bosutinib 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE 5-hydroxynaphthalene-1-sulfonamide N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide N-phenyl-1H-pyrazole-3-carboxamide 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
CDK4 and CDKN2A	cyclin-dependent kinase 4	cyclin-dependent kinase inhibitor 2A	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence
CDK4 and CDKN2B	cyclin-dependent kinase 4	cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Cellular Senescence Oncogene Induced Senescence TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Mitotic G1-G1/S phases TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer G1 Phase Senescence-Associated Secretory Phenotype (SASP) TGFBR1 KD Mutants in Cancer Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer Cyclin D associated events in G1 Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex Oxidative Stress Induced Senescence SMAD4 MH2 Domain Mutants in Cancer
CDK5 and ERBB3	cyclin-dependent kinase 5	erb-b2 receptor tyrosine kinase 3	Signaling by GPCR Axon guidance Semaphorin interactions Opioid Signalling DARPP-32 events CRMPs in Sema3A signaling Factors involved in megakaryocyte development and platelet production		Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
CDK5 and PTPN2	cyclin-dependent kinase 5	protein tyrosine phosphatase, non-receptor type 2	Signaling by GPCR Axon guidance Semaphorin interactions Opioid Signalling DARPP-32 events CRMPs in Sema3A signaling Factors involved in megakaryocyte development and platelet production		Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
CDK5 and PPARG	cyclin-dependent kinase 5	peroxisome proliferator-activated receptor gamma	Signaling by GPCR Axon guidance Semaphorin interactions Opioid Signalling DARPP-32 events CRMPs in Sema3A signaling Factors involved in megakaryocyte development and platelet production	PPARA activates gene expression Fatty acid, triacylglycerol, and ketone body metabolism Metabolism of lipids and lipoproteins Generic Transcription Pathway Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)	Indirubin-3\'-Monoxime Olomoucine Hymenialdisine SU9516 Flavopiridol Alsterpaullone 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE	Icosapent Troglitazone Mesalazine Indomethacin Rosiglitazone Nateglinide Sulfasalazine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Pioglitazone Mitiglinide Bezafibrate (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid ALEGLITAZAR
CDK6 and CDKN2A	cyclin-dependent kinase 6	cyclin-dependent kinase inhibitor 2A	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence

Search Results for: Diabetes